Rapid Response - COVID-19 Rapid Screening Test [Box of 5]
Please note that all deliveries can be made from Monday, January 31, 2021.
The Rapid Response™ Antigen Testing Device is the perfect screening tool for organizations wanting to try to protect their workplace from the risk of COVID-19-related lockdowns.
Used as part of a comprehensive rapid testing program for COVID-19, the BTNX nasal device provides fast, easy-to-use, and reliable testing. Testing all staff 1-2 times per week will help detect the virus early and reduce the likelihood of spreading COVID-19.
Rapid Response COVID-19 Antigen Rapid Test Device™. It is an efficient, accurate and reliable test method that can be used by any healthcare professional. It is easy to use and gives results in 15 minutes!
The BTNX Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic test for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretion samples.
The Rapid Response™ COVID-19 Rapid Antigen Test Device is an in vitro immunochromatographic test for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions of suspected COVID individuals -19 within 6 days of onset of symptoms. This test is authorized for use at the Point of
Care, that is, in patient care settings.
The results concern the identification of the SARS-CoV-2 viral nucleoprotein antigen. Antigens are usually detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status.
Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of the disease. Laboratories are required to report all positive results to the appropriate public health authorities.
Negative results should be treated as presumptive and do not exclude SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including control decisions infections. Negative results should be considered in the context of the patient's recent exposures, history, and presence of clinical signs and symptoms consistent with COVID-19, and confirmed by molecular testing, if necessary, for the patient
The Rapid Response™ COVID-19 Antigen Rapid Test Device is intended for use by qualified laboratory personnel or healthcare professionals.
By purchasing this product, you agree to follow the manufacturer's intended use and terms of sale for this website.
|Sensitivity||78.6% - 96.2%|
|Specificity||96.5% - 100%|
|The duration of the conversation||6-18 months|
|Result time||15 minutes|
|Sampling technique||Shallow nasal|